Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2022-01-11 Director's Dealing
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-11 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate updates. The text specifically mentions the posting of a revised corporate slide presentation on the company's website and attaches this presentation as Exhibit 99.1. The document does not contain detailed financial statements or comprehensive financial analysis but rather an update on clinical trial plans and corporate presentation availability. The length of the document (7,254 characters) and the nature of the content indicate it is an announcement of a report (the investor presentation) rather than the report itself. Therefore, this filing is best classified as an Investor Presentation (IP).
2022-01-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details amendments to the company's bylaws, including changes to officer appointments and jurisdiction provisions. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The focus is on governance changes, specifically amendments to the articles of incorporation or bylaws. According to the filing definitions, announcements of changes in the company's board or senior management or governance documents fall under Board/Management Information (MANG). However, since this is about amendments to bylaws, which are governance documents, it aligns more closely with Governance Information (CGR). But the document is a Form 8-K current report announcing these changes, which is typically classified under Regulatory Filings (RNS) as it is a regulatory announcement of a governance change rather than the governance report itself. Given the document length and content, it is not a brief announcement but a full Form 8-K filing. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2022-01-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.